Publications by authors named "S Monteverdi"
Estrogen receptor (ER)-positive breast cancer (BC) is the most common BC subtype. Endocrine therapy (ET) targeting ER signaling still remains the mainstay treatment option for hormone receptor (HR)-positive BC either in the early or in advanced setting, including different strategies, such as the suppression of estrogen production or directly blocking the ER pathway through SERMs-selective estrogen receptor modulators-or SERDs-selective estrogen receptor degraders. Nevertheless, the development of de novo or acquired endocrine resistance still remains challenging for oncologists.
View Article and Find Full Text PDFArticle Synopsis
- Endocrine therapy (ET) is a primary treatment for estrogen receptor-positive breast cancer, using tools like aromatase inhibitors and medications such as tamoxifen to block estrogen signaling.
- Resistance to ET, either from the start or after treatment, is a major reason for therapy failure and cancer progression, largely due to changes in the ESR1 gene.
- New oral selective estrogen receptor degraders are being developed that can effectively target and overcome these resistance issues by reducing ER protein levels and blocking estrogen's effects, offering hope for better treatment outcomes.
Background: Bone mineral density (BMD) lacks sensitivity in individual fracture risk assessment in early breast cancer (EBC) patients treated with aromatase inhibitors (AIs). New dual-energy X-ray absorptiometry (DXA) based risk factors are needed.
Methods: Trabecular bone score (TBS), bone strain index (BSI) and DXA parameters of bone geometry were evaluated in postmenopausal women diagnosed with EBC.
Background: KRAS is the most frequently mutated gene in non-small cell lung cancer (NSCLC), however conflicting data are available on its role as a biomarker.
Objective: The aim of our work was to investigate the impact of KRAS mutations on response and survival outcomes in advanced non-squamous NSCLC patients treated with immune checkpoint inhibitors alone or in combination with chemotherapy.
Patients And Methods: We retrospectively identified 119 patients, most of whom (58%) were KRAS wild type.
Introduction: Whether adjuvant therapy with aromatase inhibitors (AIs) causes sleep disturbances or not in postmenopausal women with early breast cancer (EBC) is still a controversial issue.
Methods: Between March 2014 and November 2017, validated questionnaires for assessing insomnia, anxiety, depression, quality of life (QoL) and restless legs syndrome (RLS) were administered to 160 EBC patients at baseline and after 3, 6, 12, and 24 months of AI therapy.
Results: AI therapy significantly decreased the patients' QoL, but did not influence insomnia, anxiety or depression.